The availability and affordability of orphan drugs for rare diseases in China

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Gong, Shiwei ^a   Wang, Yingxiao ^a   Pan, Xiaoyun ^b   Zhang, Liang ^a   Huang, Rui ^a   Chen, Xin ^a   Hu, Juanjuan ^a   Xu, Yi ^a   Jin, Si ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Affordability; Availability; China; Orphan drug; Price; Rare disease

Indexed keywords

HOMOHARRINGTONINE; ORPHAN DRUG;

ARTICLE; CHINA; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MARKETING; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH INSURANCE; HIGHEST INCOME GROUP; HUMAN; INTERNATIONAL COOPERATION; MIDDLE INCOME GROUP; RARE DISEASE; URBAN POPULATION; DRUG MANUFACTURE; HEALTH CARE COST; PRIVATE SECTOR; PUBLIC SECTOR; STATISTICS AND NUMERICAL DATA;

CHINA; HEALTH EXPENDITURES; HUMANS; ORPHAN DRUG PRODUCTION; PRIVATE SECTOR; PUBLIC SECTOR; RARE DISEASES;

EID: 85007414204     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0392-4     Document Type: Article

References (40)

1. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3-4):163-72.
2. Dunoyer M. Accelerating access to treatments for rare diseases. Nat Rev Drug Discov. 2011;10(7):475-6.
3. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039-41.
4. Wang JB, Guo JJ, Yang L, Zhang YD, Sun ZQ, Zhang YJ. Rare diseases and legislation in China. Lancet. 2010;375(9716):708-9.
5. Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(4):1009-24.
6. Cote T, Kelkar A, Xu K, Braun MM, Phillips MI. Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov. 2010;9(1):84.
7. GoodRx. Prices, Coupons and information. 2013. Accessed 13 November 2013
8. Gong S, Jin S. Current progress in the management of rare diseases and orphan drugs in China. Intractable Rare Dis Res. 2012;1(2):45-52.
9. World Health Organization and Health Action International. Measuring medicine prices, availability, affordability and price components 2nd Edition. 2008. http://www.who.int/medicines/areas/access/medicines-prices08/en/. Accessed 29 May 2012.
10. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240-9.
11. Yang H, Dib HH, Zhu M, Qi G, Zhang X. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan. 2010;25(3):219-29.
12. Jiang M, Zhou Z, Wu L, et al. Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future. Int J Clin Pharm. 2015;37(1):12-7.
13. World Health Organization. Description of essential medicines. 2015. http://apps.who.int/medicinedocs/en/d/Js4875e/5.2.html. Accessed 17 December 2015.
14. Dove ES, Barlas IO, Birch K, et al. An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics". Omics. 2015;19(8):435-42.
15. Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics. 2011;29(1):63-82.
16. U.S. Foo. and Drug Administration. Search Orphan Drug Designations and Approvals. 2013. http//www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 31 July 2013
17. European Medicines Agency. European public assessment reports: Orphan medicines. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar-search.jsp&mid=WC0b01ac058001d125&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=orphan. Accessed 17 July 2013
18. Ministry of Health, Labour and Welfare of Japan. List of products designated as orphan drugs for diseases 2014. 2014. http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan-drug.html. Accessed 27 March 2014.
19. Food and Drug Administration of China. Data Search. 2013. http://app1.sfda.gov.cn/datasearch/face3/dir.html. Accessed 28 December 2013.
20. World Health Organization. ATC/DDD Index 2013. 2013. http://www.whoccno/atc-ddd-index/ Accessed 2 May 2013.
21. Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9(7):519-22.
22. U.S. Foo. and Drug Administration. What Are Generic Drugs? 2009. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm. Accessed 2 December 2013
23. Menn SG Price, availability and affordability: An international comparison of chronic disease medicines. 2006. http://apps.who.int/medicinedocs/index/assoc/s14135e/s14135e.pdf. Accessed 8 July 2012.
24. National Bureau of Statistics of China. Income of Urban and Rural Residents in 2011. 2012. http://www.stats.gov.cn/english/NewsEvents/201201/t20120130-26566.html. Accessed 30 May 2013.
25. Ministry of Human Resources and Social Security of the People's Republic of China. Drug lists of National Basic Medical Insurance. 2009. http://www.gov.cn/gzdt/2009-11/30/content-1476934.htm. Accessed 30 November 2013
26. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012; 11(4):267-8.
27. Ling RE, Liu F, Lu XQ, Wang W. Emerging issues in public health: a perspective on China's healthcare system. Public Health. 2011;125(1):9-14.
28. Shao S, Zhao F, Wang J, et al. The ecology of medical care in Beijing. PLoS ONE. 2013;8(12):e82446.
29. Gong SW, Zhang L, Jin S, Li LL. Management strategy for raising the accessibility to orphan drugs in China. Chin J Hospital Admin. 2010;26(2):126-30.
30. Zheng S, Song M, Wu L, et al. China: public health genomics. Public Health Genom. 2010;13(5):269-75.
31. Barak A, Shankar NJ. Orphan drugs: pricing, reimbursement and patient access. Int J Pharmaceut Healthcare Market. 2011;5(4):299-317
32. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23-9.
33. J P. Improving patient access to orphan drugs in Europe. 2012. http://www.eurordis.org/content/improving-patient-access-orphan-drugs-europe Accessed 20 November 2013.
34. Communities E. High Level Pharmaceutical Forum 2005-2008 Conclusions and Recommendations. 2008. http://bookshop.europa.eu/en/high-level-pharmaceutical-forum-2005-2008-pbND3008692/ Accessed 18 July 2014.
35. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
36. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829-36.
37. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1-3.
38. Pierce D. Orphan Drugs Part 1 - Patient Care to the Individual Level. Oncol Issues. 2010;25(6):44.
39. The LPL Deficiency Association. Patient Assistance Programs. 2014. http://lplda.org/lpld-patients-and-caregivers/resources/patient-assistance/. Accessed 17 July 2014
40. Food and Drug Administration of China. 2013 China Drug Review Annual Report. 2014. http://www.cde.org.cn/news.do?method=viewInfoCommon&id=313280. Accessed 19 July 2014